Clinical Practice: All the procedures in Study will be conducted as per Clinical practice for the pathology and all the samples will be collected according to ELN guidelines.
There are no additional procedures but will be additionally collected up 20ml of peripheral blood and up to 15ml of Bone Marrow Aspirate at the same time of clinically indicated diagnostic procedures.
Study summary
The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Any gender,
* Adults (\>18 years old),
* New suspect diagnosis of acute myeloid leukemia (ELN2022 Criteria)
* Capable of comprehend the study and the consent form,
* Willing to sign the informed consent for the study.
For the retrospective population we will select:
biological samples (BM Biopsies, BM Aspirates and PB) already banked upon research purpose informed consent and collected from the 01/06/2006 up to 01/06/2024 from adults patients with diagnosis of acute myeloid leukemia according to ELN2017 Criteria.
Exclusion Criteria:
* Pediatric patients (\<18 years old),
* Patients unable or unwilling to sign the informed consent.
Primary outcome measure(s)
Inflammasome Activity — At diagnosis, in case of treatment failure and at 6 months after first line chemotherapy initiation The outcome variable is the inflammasome activation in AML blasts (PB e BM)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
